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Abstract 
Purpose: To investigate the role of serum amyloid component P (SAP) on Ras/MAPK pathway in the 
development of breast cancer (BC) via regulation of chemokine (CC motif) ligand 1 (CCL-1). 
Methods: Breast cancer (BC) and metastasis models were established using SAP-Tg transgenic mice 
and WT C57BL/6 mice. The effect of SAP on growth and metastasis was observed. Differentially 
expressed proteins in SAP-Tg and C57BL/6 serum were analyzed, and further determined by enzyme-
linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR). The effect of 
SAP on CCL1/Ras/MAPK signaling pathway was studied by immunoblotting. 
Results: Compared with WT control, SAP-Tg BC model showed a significant reduction in tumor volume 
and prolonged survival (p < 0.05). In the lung metastasis model, SAP-Tg mice showed a decreased 
number of nodules on the organ surface (p < 0.05). Protein microarray screening results showed that 
SAP inhibited CCL-1 expression (p < 0.05). CCL-1 mRNA level in SAP-Tg mice was significantly lower 
than WT control (p < 0.05). After stimulating RAW cells (mouse macrophage line) with SAP recombinant 
protein, ELISA results showed that CCL-1 secretion significantly decreased (p < 0.05). In both models, 
P38 and ERK1/2 activation in SAP-Tg mice were significantly lower than that in C57BL/6 mice. 
Conclusion: SAP inhibits the growth and metastasis of BC, possibly by reducing the secretion of CCL-
1 and inhibiting Ras/MAPK signaling pathway, thus suggesting a possible treatment strategy for breast 
cancer. 
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Serum amyloid P (SAP), C-reactive protein 
(CRP) and PTX3 belong to pentraxins. SAP is 
expressed by liver cells and regulated by a range 
of cytokines such as IL-1, IL-6 and TNF-alpha. 
CCL-1 is the first discovered CC-class 
chemokine, which is mainly secreted by activated 
immune cells such as T cells, mast cells and 
macrophages. CCR8 is the only receptor of CCL-
1 as currently known. Studies have shown that 
CCL-1 can regulate neurotransmitters and affect 
neuropathic pain, regulate the migration of nerve 
cells [1], promote the normal development of 
thymus, and play an important role in allergic 
reactions and asthma. CCL-1/CCR8 expression 
has been found in leukemia and lymphoma. They 
can protect against apoptosis of T lymphocytes 
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and leukemia cells through an autocrine 
mechanism [2].  
 
In gastric cancer, overexpression of CCL-1 may 
cause down-regulation of non-coding RNA 
GAS5, which in turn affects the ability of cells in 
vitro, and ultimately promotes proliferation and 
inhibits apoptosis of gastric cancer cells [3]. 
There are reports that CCR8 is highly expressed 
in colorectal cancer and that CCL-1 can promote 
the migration of SW480 cells, but has no effect 
on their proliferation [4]. The migration of UMUC3 
and 5637 cells was significantly enhanced when 
overexpressing CCL-1 [5]. Recent studies have 
shown that malignant melanoma cells could 
overexpress CCR8, and their adjacent lymphatic 
vessels showed CCL-1 expression. The inhibition 
of CCR8 expression can suppress the migration 
of tumor cells, and recombinant CCL-1 factors 
can promote the migration of CCR8 + tumor cells 
[6]. CCL-1 is closely related to apoptosis of tumor 
cells. MAPK signal pathway is resistant to CCR8-
dependent CCL-1, which can promote the 
phosphorylation of ERK by overexpression of 
CC5-1 in BW5147 cells and promote apoptosis. 
CCL-1 may play a role through the MAPK 
signaling pathway [7]. 
 
MAPK is a highly conserved silk/threonine 
protein kinase, mostly expressed in most 
mammalian cytoplasm and nucleus [8]. Studies 
have shown that P38 MAPK signaling pathway is 
involved in the development of cell apoptosis 
through caspase [9], and caspase can activate 
JNK and P38 MAPK, causing some 
transcriptional protein expression (Fas, P53, etc), 
and ultimately induce cell apoptosis [10]. In order 
to reveal the effects of SAP on the growth and 
metastasis of mouse breast cancer (BC), we 




Animal studies and mouse model 
establishment 
 
The animals were raised at Department of 
Animal Experiment Center, Second Hospital of 
Shandong University. All the animal procedure 
were approved by Emory Institutional Animal 
Care and Use Committee and the approval 
reference number is KYLL-2016(GJ)A-0033. A 
high standard of pre- and post-operative care 
was applied in accordance with the appropriate 
international guidelines for animal studies [11].  
The SAP-Tg transgenic mice (SAP 
overexpressed) was established by cloning 
cDNA of mSAP into the vector. The detailed 
procedure are as followed: First, the plasmid was 
linearized and then injected into fertilized eggs 
and give birth to chimeric (SAP-Tg +/-) mice. 
Chimeric (SAP-Tg +/-) mice were screened and 
the positive rate was about half. Secondly, by 
chimeric mice (SAP-Tg +/-) match, we obtained 
the SAP-Tg(+/+) mice. And then the SAP-Tg(+/+) 
mice backcrossed with C57BL/6 mice at least 8 
bands. Finally, the obtained C57BL/6 mice were 
identified several times to obtain a SAP-Tg(+/+) 
C57BL/6.  
 
BC model was established with freshly prepared 
methyl nitrosourea solution (MNU, 5 mg/ml, 
prepared with acetic acid, pH6.0). Mice were i.p. 
injected with MNU (50 mg/kg) and observed for 5 
weeks. The mouse mammary gland was felt 
every day after the injection which confirmed that 
a period of 5 weeks was enough for tumor 
formation. 
 
For the metastasis model, MCF-7 cell 
suspension (5 × 106 cells) was inoculated 
through the tail vein. Lung metastasis was 
established in 18-21 days. The lungs were 




After the tissue was removed, it was fixed in 
formalin overnight, dehydrated, embedded, 
placed in 4 oC for cooling, and sectioned in 
paraffin into 4-μm sections. The slices were 
baked for 1 h at 65 oC, and underwent dewaxing 
according to standard protocols. After washing 3 
times with PBS buffer (once 5 min), sections 
were boiled with sodium citrate buffer solution 
(pH = 6.0), and then washed three times with 
buffer with PBS (once 5 min). Sections were 
treated with 0.3 % hydrogen peroxide at room 
temperature for 30 min, washed 3 times with 
PBS, and incubated with the primary antibody 
(anti-Ki67, CST, USA) overnight. The next day, 
sections were washed at room temperature and 
secondary antibody (1: 100, with 1 % BSA) 
incubated for 40 min, and washed 3 times. The 
sections were DAB stained washed again and 
stained with hematoxylin for 3 min. For negative 
control, PBS was applied instead of the primary 
antibody. 
 
H & E staining 
 
The procedure was as follow: Dewaxing (xylene 
I, II, each 20 min), anhydrous ethanol (15 min), 
anhydrous ethanol (15 min, 95 % alcohol (10 
min), 95 % Alcohol (10 min), 80 % alcohol (5 
min), 70 % alcohol (5 min), water (3 min). 
Sections were immersed into the hematoxylin 
dye for 5 min, and then washed with water for 5 
min, and then placed in the eosin dye for 20 s 
and washed. After dehydration, neutral gum was 
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added to the sections and covered with 




Reverse transcription kit was purchased from 
TaKaRa company. Trizol was added to the cells 
and centrifuged (12000 r/min) for 10 min at 4 oC. 
The supernatant was transferred to a new EP 
tube and placed on ice for 5 min. The 
supernatant was added to one-fifth volume of 
chloroform (compared to Trizol), rapidly vortex 
shocked for 15 s, and placed on ice for 3 min. 
The samples were then centrifuged (12000 rpm) 
for 15 min at 4 oC. The upper layer was 
transfered to a new EP tube and added to equal 
volume of isopropyl alcohol. Again, the mixture 
was centrifuged (12000 rpm) for 15 min at 4 oC, 
and the supernatant was discarded. Seventy five 
percent ethanol (in DEPC water) was added and 
mixed. After centrifugation at 4 ℃ (12000 rpm) 
for 5 min, the supernatant was discarded. The 
liquid RNA was slightly dried and added 20 μL 
DEPC water. Real-time qPCR was performed as 












The reaction procedure was as follows: pre-
denaturation 95ºC, 10min; denaturation at 95 ºC, 
30 s; annealing 55 ºC, extension at 72 ºC for 30 




CCL-1 ELISA Kit was purchased from 
Guangzhou Ruibo Biotechnology Co., Ltd. One 
hundred microliters of sample and standard were 
added per well. They were incubated at 37 oC for 
90 min, and then 100 μL Biotin-labeled antibody 
were added and incubated for 60-min at 37 oC. 
The plate was washed 3 times with 0.01M TBS 
for and 100 μL ABC was added per well and 
incubated at 37 oC for 30 min. It was washed 
again 5 timeswith 0.01M TBS before TMB dark 
reaction at 37 oC for 30 min. The reaction was 




Protein was extracted with the protein extraction 
kit from Beyotime Co. The protein lysate was 
added to 20 times the volume of the tissue. The 
amount of protein was quantified using the BCA 
Kit from Thermo Fisher. The BCA solution was 
prepared at a ratio of A: B = 50: 1, then 2 μL of 
protein extract, 18 μl PBS, and 200 μl of AB 
mixture were added to each well. For 
electrophoresis, 20 μL protein was loaded. The 
electric voltage was: 80 V in the stacking gel and 
120 V in the separation gel. The protein was 
transferred to PVDF membrane under a constant 
current (250 mA) at 4 oC. The membranes were 
blocked with 5 % TBST-skim milk for 1 h at 37 
oC, and then incubated overnight at 4 °C with 
primary antibodies. The blots were then 
incubated with the secondary antibodies. After 
washing (3 times), the blots were immersed in 





Orbital blood was collected and centrifuged. The 
supernatant was stored at -70 oC. Protein 
microarray kit (Angfei Co., USA) was reheated 
for 1h at RT. The protein concentration was 
determined using the BCA method, and the total 
protein concentration was adjusted to 500 
μg/mL. Two arrays were placed in a capsule, and 
an equal volume of 200 μL samples were added 
and incubated for 2 h in the dark. After washing 
(3 times each 5min), the primary antibodies (1: 
100) were added and incubated at 4 oC 
overnight. Then the arrays were washed (3 times 
each 5min) and the secondary antibodies (1: 
100) were added1 h later, the film was washed 
and incubated with the developer (Thermo Fisher 
Co., Ltd. USA) for 2 min. The blots were 




Data were analyzed by SPSS. Student’s t-test 
was used to identify significant differences. In all 
cases, p < 0.05 was considered to be statistically 
significant. *P < 0.05, **p < 0.01, ***p < 0.001. 
Image Pro Plus was applied to analyze the grey 




Effect of SAP on the growth of mouse breast 
cancer 
 
In order to study the effect of SAP on the growth 
of BC in mice, we established a mouse BC 
model, and analyzed the tumor volume and the 
survival rate of different mice. SAP-Tg mice 
showed a significantly lower volume compared 
with the C57BL/6 mice (Figure 1A). The tumor 
weight of SAP-Tg mice was significantly lower 
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than that of the C57BL/6 mice (Fig. 1B, p < 
0.05).Also, transgenic mice had a significantly 
longer overall survival than C57BL/6 (Figure 1C, 
p < 0.01). To further determine proliferation level 
of the tumors in the different groups, BrdU 
staining was performed. The SAP-Tg mice 
showed a lower level of BrdU+ cell number than 
the C57BL/6 mice (Figure 1D, p < 0.01). The 
above results suggested a strong anti-tumor 
effect of SAP in BC development. 
 
Effect of SAP on metastasis of mouse breast 
cancer 
 
To further investigate the effect of SAP on lung 
metastasis, we established a lung metastasis 
model using tail vein injection. After inoculation, 
we counted the number of tumor nodules on the 
surface of all lung lobes. Consistent with the 
tumor growth results, SAP-Tg mice exhibited 
fewer metastatic nodules in their lungs than 
C57BL/6 (Fig. 2A, B, P<0.01). Using H&E 
staining, the total number of metastatic nodules 
inside of lungs were counted, which was also 
lower in SAP-Tg mice compared with the 
C57BL/6 group (Figure 2C, p < 0.01). 
 
SAP regulates CCL-1 secretion by 
macrophages 
 
We collected the orbital blood and obtained the 
serum by centrifugation. The cytokine CCL-1 in 
the serum was determined. The SAP-Tg mice 
 
 
Figure 1: Effect of SAP on the growth of mouse breast cancer (BC). (A) the tumor volumes of BC induced in 
different strains; (B) the tumor weights; (C) the survival time of SAP-Tg mice was significantly longer than that of 
C57BL/6 mice; (D) SAP-Tg mice showed significantly less BrdU immune-active cells than C57BL/6 mice; *p < 
0.05, ** p < 0.01 
 
 
Figure 2: Effect of SAP on the metastasis of mouse BC. (A) tumor nodules on the lung surface. (B) 
SAP-Tg mice had fewer tumor nodules on the lung surface compared with C57BL/6 mice. (C) H&E 
staining demonstrated fewer total number of metastatic nodules inside of lungs in SAP-Tg mice; *p < 
0.05, ** p < 0.01, *** p <0.001 
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showed a significantly lower levelofCCL-1 
compared with C57BL/6 mice, as demonstrated 
by the RayBiotech protein microarray (Figure 
3A). For further confirmation, quantitative PCR 
was performed and the results showed that the 
CCL-1 mRNA level in the peripheral blood of 
SAP-Tg mice was significantly lower (Fig. 3B, 
P<0.05). The protein expression of CCL-1 was 
further determined using the mouse CCL-1 
ELISA kit. For normal individuals, two strains had 
similar CCL-1 expression in the serum. However, 
in tumor-bearing groups, the expression of CCL-
1 in SAP-Tg mice was significantly lower than 
that in C57BL/6 mice (p < 0.01, Figure 3C).  
 
In the lung metastasis models, SAP-Tg mice also 
showed lessCCL-1 expression in the serum 
(Figure 3D, p < 0.01). Given CCL-1 was mainly 
secreted by macrophages, we further examined 
SAP generation through the secretion from 
macrophages. First, we recovered the 
macrophage cell line RAW264.7, followed by 
SAP administration (50 ng/mL) or the same 
amount used for treatment. After 24 h, the 
supernatant was collected for CCL-1 ELISA 
assay. Compared with DMSO (the vehicle), CCL-
1 secretion from the SAP-treated cells was 
significantly decreased (Figure 3E, p < 0.05). 
 
SAP affects the Ras/MAPK signaling pathway 
in breast cancer 
 
To further investigate whether SAP affects the  
activation of P38, ERK1/2 and K-ras through 
CCL-1, we examined these signaling by Western 
blotting. As shown in Figure 4A, p-P38 and p-
ERK level were significantly lower in the SAP-Tg-
mice established BC model compared with the 
WT (P < 0.01). Similarly, in the metastasis model 
(Figure 4B), SAP-Tg mice exhibited not only 
decreased expression o fp-P38, p-ERK but also 




SAP is a serum protein expressed by liver cells. 
It is upregulated after acute inflammation in mice, 
but not in the human body. To date, little is yet 
known about the roles of SAP on growth and 
metastasis of BC tumor. Through our screening, 
we found a lower CCL-1 expression in the SAP-
Tg mice compared with the WT control. 
Chemokines are a class of small molecules, 
which promote leukocyte migration toward 
themselves [12]. CCL-1 is among the first 
discovered CC class of chemokines, which are 
mainly secreted by activated T cells, mast cells 
and macrophages [13-17]. Recently, it has been 
shown that autocrine CCL-1 produced from 
leukocellular lymphoma and adult cell leukemia 
has an anti-apoptotic effect [18]. Around the 
lymph node margins, endothelial cells secret 
CCL-1 and cause a high expression of CCR8, 
thereby affecting the growth of breast cancer and 
lymphatic metastasis. 
 
Figure 3: SAP affects BC development via regulating CCL-1 secretion by macrophages. (A) RayBiotech protein 
microarray. (B) CCL-1 mRNA expression in the peripheral blood of SAP-Tg or WT mice. (C-D) CCL-1 protein 
level in the peripheral blood of BC model (C) and lung metastasis model (D). (E) CCL-1 secreted by 
macrophages after stimulation with DMSO or SAP; p < 0.05, ** p < 0.01, ***p < 0.001 
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Figure 4: Effect of SAP on Ras/MAPK signaling in breast cancer and lung metastasis model. (A) Expression of 
P38, ERK1/2, p-P38, p-ERK1/2, and K-ras in tumor tissue of the BC mice model; (B) Expression of P38, ERK1/2, 
p-P38, p-ERK1/2, and K-ras in tumor tissue of the metastasis mice model; *p < 0.05, **p < 0.01, ***p < 0.001 
 
This study was to investigate the effect of SAP 
on in vivo growth and metastasis of BC. We used 
protein Microarray technology to probe the 
mechanism under lying the inhibition of SAP on 
growth and metastasis, and observed a 
significant difference in CCL-1 expression 
between SAP-Tg mice and WT control. This 
difference was validated by Real-time PCR and 
ELISA assay. We demonstrated the role of SAP 
on CCL-1 secreted by macrophages. Given CCL-
1 could also be secreted by T cells and mast 
cells, we cannot exclude the involvement of T 
cells and mast cells so far. This is a limitation of 
the present work and is to be addressed in a 
further study. 
 
CCL-1 may promote the proliferation and 
migration of tumor cells through MAPK signaling 
pathway [19]. It has been widely reported that 
p38 and JNK inhibitors can suppress the 
proliferation of tumor cells by inhibiting gastrin 
expression [20]. Gastrin can promote the 
proliferation of Colo320 cells by inhibiting p38 
activation [21]. ERK MAPK signal pathway has a 
key function for tumor cell invasion, drug 
resistance and so on. In our subcutaneously 
implanted BC model and the metastasis model, 
activation (phosphorylation) of P38 and ERK in 
the SAPTg mice were significantly lower than the 
WT control; and K-ras was even more reduced in 
the metastasis model. These findings were 
consistent with the known tumor promoting role 




The findings of this study indicate that SAP 
significantly inhibits BC growth and metastasis in 
mice. SAP inhibits macrophage-secreted CCL-1, 
thereby attenuating the activation of CCL-1-
Ras/MAPK axis. SAP can be used as a novel 
factor for understanding the mechanism of BC 
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